IRLAB Therapeutics AB (OSTO:IRLAB A) Days Sales Outstanding : 326.18 (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Days Sales Outstanding?

IRLAB Therapeutics AB's average Accounts Receivable for the three months ended in Mar. 2025 was kr15.59 Mil. IRLAB Therapeutics AB's Revenue for the three months ended in Mar. 2025 was kr4.36 Mil. Hence, IRLAB Therapeutics AB's Days Sales Outstanding for the three months ended in Mar. 2025 was 326.18.

The historical rank and industry rank for IRLAB Therapeutics AB's Days Sales Outstanding or its related term are showing as below:

OSTO:IRLAB A' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.85 Med: 43.44 Max: 385.28
Current: 95.84

During the past 12 years, IRLAB Therapeutics AB's highest Days Sales Outstanding was 385.28. The lowest was 7.85. And the median was 43.44.

OSTO:IRLAB A's Days Sales Outstanding is ranked worse than
66.75% of 848 companies
in the Biotechnology industry
Industry Median: 70.36 vs OSTO:IRLAB A: 95.84

IRLAB Therapeutics AB's Days Sales Outstanding increased from Mar. 2024 (0.00) to Mar. 2025 (326.18).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

IRLAB Therapeutics AB Days Sales Outstanding Historical Data

The historical data trend for IRLAB Therapeutics AB's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Days Sales Outstanding Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Sales Outstanding

Get a 7-Day Free Trial

7.85

23.26

213.55

IRLAB Therapeutics AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Days Sales Outstanding	Get a 7-Day Free Trial															-	81.33	390.22	25.85	326.18

Competitive Comparison of IRLAB Therapeutics AB's Days Sales Outstanding

For the Biotechnology subindustry, IRLAB Therapeutics AB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRLAB Therapeutics AB's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Days Sales Outstanding falls into.

Save Embed

;

Save Embed

;

IRLAB Therapeutics AB Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

IRLAB Therapeutics AB's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

	Days Sales Outstanding (A: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	94.628	*	365
=	0					/	94.628	*	365
=	0.00

IRLAB Therapeutics AB's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding (Q: Mar. 2025 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2024 )	+	Accounts Receivable (A: Mar. 2025 ))	/	count )	/	Revenue (A: Mar. 2025 )	*	Days in Period
=	( (0	+	15.585)	/	1 )	/	4.36	*	365 / 4
=	15.585					/	4.36	*	365 / 4
=	326.18

IRLAB Therapeutics AB (OSTO:IRLAB A) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

IRLAB Therapeutics AB Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

IRLAB Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines